Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|May 24, 2017
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cellsJenni Nikkilä, Rahul Kumar, James Campbell, et al.
Molecular Oncology|October 22, 2023
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7Joseph S Baxter, Rachel Brough, Dragomir B Krastev, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in BRCA1/2-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Science (New York, N.Y.)|April 4, 2020
Structural basis for allosteric PARP-1 retention on DNA breaksLevani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, et al.
Scientific Data|March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cellsStephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Nature Cell Biology|January 11, 2022
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatinDragomir B Krastev, Shudong Li, Yilun Sun, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Pageof 6